Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recurrent malaria after ACT treatment in Ghanaian children
PACTR202603660167879Phase 4Recruiting
- Sponsor
- Kumasi Centre for Collaborative Research in Tropical Medicine
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of artesunate, pyronaridine, artemether and lumefantrine in malaria and Malaria (2 arms), sponsored by Kumasi Centre for Collaborative Research in Tropical Medicine. Primary endpoints: Day 28 PCR-corrected adequate clinical and parasitological response and Day 42 PCR-corrected adequate clinical and parasitological response. Started Jan 2024; status: recruiting.
02
Drugs
artesunatepyronaridineartemetherlumefantrine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on PACTR202603660167879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603660167879.